Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMU48OD)

Drug Name
SR-973 Drug Info
Synonyms
SR-973; CHEMBL204357; SCHEMBL4486832; ZINC34801833; BDBM50182403; (2S,3R)-N1-hydroxy-3-isobutyl-N4-((S)-2-oxo-1-(3-phenoxybenzyl)azepan-3-yl)-2-propylsuccinamide; (2R,3S)-N'-Hydroxy-N-[1-(3-phenoxybenzyl)-2,3,4,5,6,7-hexahydro-2-oxo-1H-azepine-3beta-yl]-2-isobutyl-3-propylbutanediamide
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
9849669
TTD Drug ID
DMU48OD

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Approved Drug(s)
Investigative Drug(s)
Preclinical Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Matrix metalloproteinase-13 (MMP-13)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [2]
Apratastat DM8W4N9 Rheumatoid arthritis FA20 Phase 2 [3]
PMID17935984C1 DMO1IHL Pain MG30-MG3Z Clinical trial [4]
PMID29130358-Compound-Figure18(14a) DMHIBTZ N. A. N. A. Patented [5]
PMID29130358-Compound-Figure16(9b) DMPAQLZ N. A. N. A. Patented [5]
PMID29130358-Compound-Figure16(9a) DMKX5R8 N. A. N. A. Patented [5]
PMID29130358-Compound-Figure18(14) DM7WXJ9 N. A. N. A. Patented [5]
PMID29130358-Compound-Figure16(9c) DM0ZRI9 N. A. N. A. Patented [5]
GM6001 DM7V9CT Corneal ulcer 9A76 Discontinued in Phase 2 [6]
RS-130830 DMOTANY Hepatitis C virus infection 1E51.1 Discontinued in Phase 2 [7]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Matrix metalloproteinase-1 (MMP-1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Prinomastat DM9HOKG Lung cancer 2C25.0 Approved [8]
Marimastat DM6V34C Pancreatic cancer 2C10 Phase 3 [9]
CIPEMASTAT DM803GL Rheumatoid arthritis FA20 Phase 3 [10]
Apratastat DM8W4N9 Rheumatoid arthritis FA20 Phase 2 [3]
PMID29130358-Compound-Figure18(14a) DMHIBTZ N. A. N. A. Patented [5]
PMID29130358-Compound-Figure10(2a) DMFWXPS N. A. N. A. Patented [5]
BMS 275291 DMKSFPE Kaposi sarcoma 2B57 Discontinued in Phase 3 [11]
GM6001 DM7V9CT Corneal ulcer 9A76 Discontinued in Phase 2 [12]
RS-130830 DMOTANY Hepatitis C virus infection 1E51.1 Discontinued in Phase 2 [7]
XL784 DMICR39 Diabetic nephropathy GB61.Z Discontinued in Phase 2 [13]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Matrix metalloproteinase-9 (MMP-9)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [14]
DP-b99 DM97S10 Stroke 8B20 Phase 3 [15]
GS-5745 DMP8MDW Gastric adenocarcinoma 2B72 Phase 3 [16]
Andecaliximab DMLDB1X Gastric adenocarcinoma 2B72 Phase 3 [17]
BLZ-100 DMFKA4G Glioma 2A00.0 Phase 1/2 [18]
Neovastat DMXTYWJ Non-small-cell lung cancer 2C25.Y Phase 1 [19]
PMID29130358-Compound-Figure18(14a) DMHIBTZ N. A. N. A. Patented [5]
PMID29130358-Compound-Figure17(12) DMML4PA N. A. N. A. Patented [5]
PMID29130358-Compound-Figure17(10) DMVA15O N. A. N. A. Patented [5]
PMID29130358-Compound-SB-3CT DMC64XQ N. A. N. A. Patented [5]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Matrix metalloproteinase-14 (MMP-14)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Epigallocatechin gallate DMCGWBJ Hepatic fibrosis DB93.0 Phase 3 [20]
BT1718 DMTXBUV Solid tumour/cancer 2A00-2F9Z Phase 1/2a [21]
GM6001 DM7V9CT Corneal ulcer 9A76 Discontinued in Phase 2 [12]
MMI270 DM38N2K Discovery agent N.A. Investigative [22]
IK-862 DMJA4UE Discovery agent N.A. Investigative [23]
2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide DMCNV5J Discovery agent N.A. Investigative [24]
[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid DM37C25 Discovery agent N.A. Investigative [24]
N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide DM4VADN Discovery agent N.A. Investigative [24]
UK-356618 DM02FGH Discovery agent N.A. Investigative [25]
PMID23631440C29e DMM92IB Discovery agent N.A. Investigative [26]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Matrix metalloproteinase-2 (MMP-2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Prinomastat DM9HOKG Lung cancer 2C25.0 Approved [8]
Epigallocatechin gallate DMCGWBJ Hepatic fibrosis DB93.0 Phase 3 [20]
Marimastat DM6V34C Pancreatic cancer 2C10 Phase 3 [9]
Neovastat DMXTYWJ Non-small-cell lung cancer 2C25.Y Phase 1 [19]
Metastat DMTQ4PN Acne vulgaris ED80 Phase 1 [27]
PMID29130358-Compound-Figure18(14a) DMHIBTZ N. A. N. A. Patented [5]
PMID29130358-Compound-Figure10(2a) DMFWXPS N. A. N. A. Patented [5]
PMID29130358-Compound-Figure16(9b) DMPAQLZ N. A. N. A. Patented [5]
PMID29130358-Compound-SB-3CT DMC64XQ N. A. N. A. Patented [5]
PMID29130358-Compound-Figure16(9a) DMKX5R8 N. A. N. A. Patented [5]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Matrix metalloproteinase-21 (MMP-21)
Drug Name Drug ID Indication ICD 11 Highest Status REF
GM6001 DM7V9CT Corneal ulcer 9A76 Discontinued in Phase 2 [28]
IK-862 DMJA4UE Discovery agent N.A. Investigative [23]
2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide DMCNV5J Discovery agent N.A. Investigative [24]
[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid DM37C25 Discovery agent N.A. Investigative [24]
N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide DM4VADN Discovery agent N.A. Investigative [24]
3-(4-(2-phenylethynyl)benzoyl)pentanoic acid DMQDPHT Discovery agent N.A. Investigative [28]
N-hydroxy-2,3-bis(phenylsulfonamido)propanamide DMZWIVJ Discovery agent N.A. Investigative [29]
⏷ Show the Full List of 7 Drug(s)
Drug(s) Targeting Matrix metalloproteinase-7 (MMP-7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Prinomastat DM9HOKG Lung cancer 2C25.0 Approved [8]
Marimastat DM6V34C Pancreatic cancer 2C10 Phase 3 [9]
BMS 275291 DMKSFPE Kaposi sarcoma 2B57 Discontinued in Phase 3 [11]
SC-44463 DMBPNKT N. A. N. A. Terminated [25]
BB-3644 DM7YRFE Solid tumour/cancer 2A00-2F9Z Terminated [30]
MMI270 DM38N2K Discovery agent N.A. Investigative [22]
IK-862 DMJA4UE Discovery agent N.A. Investigative [23]
SL422 DM3I2US Discovery agent N.A. Investigative [31]
3-Benzenesulfonyl-heptanoic acid hydroxyamide DM7XDCF Discovery agent N.A. Investigative [32]
3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide DMJSOTE Discovery agent N.A. Investigative [32]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting TNF alpha converting enzyme (ADAM17)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Apratastat DM8W4N9 Rheumatoid arthritis FA20 Phase 2 [3]
Aderbasib DMYOMSC Breast cancer 2C60-2C65 Phase 1/2 [33]
GW-3333 DM3PMAZ Chronic obstructive pulmonary disease CA22 Preclinical [34]
DPC-333 DM4JBQD Inflammatory bowel disease DD72 Terminated [34]
IK-862 DMJA4UE Discovery agent N.A. Investigative [35]
SL422 DM3I2US Discovery agent N.A. Investigative [31]
PKF-242-484 DMNDLAS Discovery agent N.A. Investigative [36]
N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide DMWXUCT Discovery agent N.A. Investigative [37]
N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl) DMA6EPH Discovery agent N.A. Investigative [37]
PKF-241-466 DM04C9V Discovery agent N.A. Investigative [36]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Amyloid beta A4 protein (APP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nirogacestat DMUP5Z0 Desmoid tumour 2F7C Approved [38]
Aducanumab DM51JW4 Alzheimer disease 8A20 Approved [39]
Lecanemab DMW03YD Alzheimer disease 8A20 Approved [40]
Florbetapir F-18 DMJ8A3Z Diagnostic imaging N.A. Approved [41]
GV-971 DMTMA5W Alzheimer disease 8A20 Approved in China [42]
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [43]
Solanezumab DM0HIU5 Alzheimer disease 8A20 Phase 3 [44]
Tramiprosate DM7BSRH Alzheimer disease 8A20 Phase 3 [45]
Bapineuzumab DMHQ5GK Alzheimer disease 8A20 Phase 3 [46]
ALZT-OP1 DMG5BTD Alzheimer disease 8A20 Phase 3 [47]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Amyloid beta A4 protein (APP) TTE4KHA A4_HUMAN Inhibitor [1]
Matrix metalloproteinase-1 (MMP-1) TTMX39J MMP1_HUMAN Inhibitor [1]
Matrix metalloproteinase-13 (MMP-13) TTHY57M MMP13_HUMAN Inhibitor [1]
Matrix metalloproteinase-14 (MMP-14) TTJ4QE7 MMP14_HUMAN Inhibitor [1]
Matrix metalloproteinase-2 (MMP-2) TTLM12X MMP2_HUMAN Inhibitor [1]
Matrix metalloproteinase-21 (MMP-21) TTYRF5E MMP21_HUMAN Inhibitor [1]
Matrix metalloproteinase-7 (MMP-7) TTMTWOS MMP7_HUMAN Inhibitor [1]
Matrix metalloproteinase-9 (MMP-9) TT6X50U MMP9_HUMAN Inhibitor [1]
TNF alpha converting enzyme (ADAM17) TT6AZXG ADA17_HUMAN Inhibitor [1]

References

1 Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63.
2 High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem. 2009 Feb 1;17(3):990-1005.
3 Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1605-9.
4 Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6529-34.
5 Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
6 Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia si... J Biol Chem. 2007 Sep 21;282(38):27781-91.
7 Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1101-6.
8 AG-3340 (Agouron Pharmaceuticals Inc). IDrugs. 2000 Mar;3(3):336-45.
9 Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007 Mar 15;559(1):75-81.
10 Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis. Infect Immun. 2014 Apr;82(4):1710-8.
11 Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Cancer. 2008 Mar 1;112(5):1083-8.
12 Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with i... Bioorg Med Chem. 2008 Sep 15;16(18):8745-59.
13 Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs. 2008 Sep;13(3):447-63.
14 Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloprote... Bioorg Med Chem. 2009 Feb 1;17(3):1290-6.
15 DP-b99 modulates matrix metalloproteinase activity and neuronal plasticity. PLoS One. 2014 Jun 11;9(6):e99789.
16 National Cancer Institute Drug Dictionary (drug id 747683).
17 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
18 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
19 Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001 Dec;28(6):620-5.
20 Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4171-4.
21 ClinicalTrials.gov (NCT03486730) BT1718 in Patients With Advanced Solid Tumours.. U.S. National Institutes of Health.
22 Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74.
23 Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7.
24 Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
25 A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem. 2003 Jul 31;46(16):3514-25.
26 Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core. J Med Chem. 2013 Jun 13;56(11):4357-73.
27 Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002 Sep;2(9):657-72.
28 Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8.
29 Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3333-7.
30 Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006 Mar;6(3):227-39.
31 Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. J Med Chem. 2001 Aug 2;44(16):2636-60.
32 Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J Med Chem. 2000 Jun 15;43(12):2324-31.
33 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
34 Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
35 Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge. Bioorg Med Chem. 2008 Oct 1;16(19):8781-94.
36 Current perspective of TACE inhibitors: a review. Bioorg Med Chem. 2009 Jan 15;17(2):444-59.
37 Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation. Bioorg Med Chem. 2008 Jan 1;16(1):530-5.
38 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
39 Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets . Immun Ageing. 2013; 10: 18.
40 The murine version of BAN2401 (mAb158) selectively reduces amyloid-beta protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis. 2015;43(2):575-88.
41 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
42 Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression. Cell Res. 2019 Oct;29(10):787-803.
43 Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J Med Chem. 2006 Oct 5;49(20):6111-9.
44 Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23;370(4):311-21.
45 Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging. 2007 Apr;28(4):537-47.
46 Bapineuzumab: anti-beta-amyloid monoclonal antibodies for the treatment of Alzheimer's disease. Immunotherapy. 2010 Nov;2(6):767-82.
47 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)